MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202511093257 A) filed by Indian Institute Of Technology Kanpur on September 29, 2025, for A Dna Methylation Signature Assay For Prognosis Of Prostate Cancer.
Inventors include Bushra; Promit Ganguly; and Sushmita Kundu.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: ABSTRACT The present invention provides an in-vitro DNA methylation signature assay for detection of prostate cancer is provided. The assay comprises a panel of 25 CpG loci identified through genome-wide DNA methylation profiling of prostate tissue specimens from an Indian cohort comprising prostate cancer and benign prostatic hyperplasia specimens. The DNA methylation profile is determined by detecting methylation at one or more of the 25 CpG loci. In a further embodiment, a subset of four CpG loci comprising cg11450947_TC11, cg19224544_TC11, cg03787864_TC11 and cg25737323_BC11 is provided for further assay evaluation. Bisulfite-PCR primer pairs are provided for detection of the four selected loci. The disclosed methylation signature provides a molecular basis for distinguishing prostate cancer-associated methylation patterns from benign prostatic hyperplasia-associated methylation patterns and may be implemented using suitable in-vitro DNA methylation detection techniques. FIG. 1
Disclaimer: Curated by HT Syndication.
